Predicted EC95 of Effect-site Concentration of Remifentanil for Preventing Cough After Laryngomicrosurgery From Propofol Anesthesia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Number of cough
研究概览
简要总结
The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.
详细描述
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ASA I-II patients undergoing general anesthesia for laryngomicrosurgery
排除标准
- •Anticipated difficult airway
- •COPD, Asthma
- •Recent URI (< 2 weeks)
- •Severe cardiac, hepatic renal disease
研究组 & 干预措施
Remifentanil
Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
干预措施: Remifentanil (Drug)
Remifentanil
Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
干预措施: Propofol anesthesia (Drug)
结局指标
主要结局
Number of cough
时间窗: from end of surgery to 5 min after tracheal extubation
Number of cough or a strong and sudden contraction of the abdomen during periextubation periods
次要结局
未报告次要终点
研究者
Jong Yeop Kim
Professor
Ajou University School of Medicine